Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with Royalty ...

Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of ...

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Canaccord Genuity analyst Caitlin Burrows initiated coverage on Orthofix Medical Inc. OFIX with a Buy rating and announced a ...

Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...

The CEO of Cytokinetics says the company is not for sale. That doesn't mean it would turn away potential suitors.

Cytokinetics could make more geography-centric deals as regulators in the United States, Europe and China review the company's potential blockbuster drug for approval. Cytokinetics Inc. has a new ...

Technical analysis for Cytokinetics Incorporated CYTK including support levels resistance levels and stop losses for CYTK ...

Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb's ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today provided guidance for corporate milestones expected to occur in 2025 and outlined its aspirational Vision 2030 ...

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research report issued to clients and investors on ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.